Interestingly, the hepatic inflammation observed during the progression of NAFLD due to lipotoxicity and the production of pro-inflammatory (e.g., TNF-α, IL-1, IL-6, IL-17) and prothrombotic factors appears to affect both the pathogenesis of NAFLD and bone tissue metabolism (14). The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.